Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 31;61(1):87. doi: 10.3892/ijo.2022.5377

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Huang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Survival analysis of CDCA5 in kidney renal clear cell carcinoma and TCGA cancers was performed using UALCA and GSCA. (A) Patients with a higher CDCA5 expression exhibited a worse overall survival (P<0.0001) compared to those with a low/medium CDCA5 expression group. (B) Kaplan-Meier curves of overall survival between groups according to CDCA5 expression level and tumor grade. Patients with a high CDCA5 expression and grade 4 ccRCC tumor had a worse survival (P<0.0001). (C) Bubble plot displaying survival between the high and low gene set variation analysis score related to CDCA5 expression. The red bubbles represented a higher hazard ratio, and bubbles with a black outline border indicate a Cox P-value <0.05. UALCA, the university of Alabama at Birmingham cancer data analysis; GSCA, Gene Set Cancer Analysis; CDCA5, cell division cycle-associated 5; ccRCC, clear cell renal cell carcinoma; OS, overall survival; DFS, disease-free survival; PFS, progression-free survival; DSS, disease-free survival; DFI, disease-free interval; ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumor; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.